AI Article Synopsis
- Researchers are exploring a new immune checkpoint called NKG2A that appears on natural killer (NK) cells and CD8 T cells, which are vital for fighting tumors.
- Two studies aim to enhance cancer treatments by blocking NKG2A, potentially improving the effectiveness of tumor-targeting antibodies and tumor-specific vaccines.
- This approach may lead to significant advancements in cancer immunotherapy, similar to previous breakthroughs in blocking other immune checkpoints.
Article Abstract
One of the major breakthroughs of cancer immunotherapy has come from blocking immune checkpoint molecules on tumor-reactive T cells. Now, two studies examine targeting of a novel immune checkpoint, NKG2A, that can be expressed on both NK cells and on CD8 T cells, either combined with a tumor-targeting antibody or with a tumor-specific vaccine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cell.2018.11.048 | DOI Listing |
Publication Analysis
Top Keywords
immune checkpoint
12
nkg2a kid
4
kid immune
4
checkpoint block
4
block major
4
major breakthroughs
4
breakthroughs cancer
4
cancer immunotherapy
4
immunotherapy blocking
4
blocking immune
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!